Weiss Asset Management LP Invests $20.27 Million in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Weiss Asset Management LP purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the first quarter, HoldingsChannel.com reports. The fund purchased 510,407 shares of the company’s stock, valued at approximately $20,273,000.

Several other large investors have also bought and sold shares of CNTA. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $36,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth $100,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CNTA. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company lowered Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Finally, B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $40.50 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $12.74 and a twelve month high of $40.56. The stock has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The company’s fifty day moving average is $40.14 and its 200-day moving average is $33.69.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.